Loading...
NPI 1861032633 · Little Rock, AR · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Natural State Genomics LLC is a clinical medical laboratory provider located in Little Rock, Arkansas. This profile covers 12 Medicare and 38 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Natural State Genomics LLC |
| Address | 10915 N Rodney Parham Rd Ste C |
| City | Little Rock |
| State | AR |
| ZIP | 72212 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 9, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $4.3M |
| Medicare | $1.2M |
NATURAL STATE GENOMICS LLC’s billing mix is dominated by molecular infectious-disease testing consistent with a clinical medical laboratory that performs amplified nucleic acid probe techniques. Its top Medicare revenue codes include 87798, 87481, and 87640, all of which are descriptions of NAAT/amplified-probe testing for infectious agents; on Medicaid the largest codes are U0004 and U0003, which are high-throughput SARS‑CoV‑2 nucleic acid detection codes. This code mix signals an operational focus on molecular diagnostic workflows and high-throughput COVID/respiratory testing modalities rather than broad anatomic pathology or routine chemistry panels.
Revenue concentration is very high for both payers: the top 3 Medicare codes account for 83.2% of the provider’s total Medicare revenue, while the top 3 Medicaid codes account for 99.1% of its Medicaid revenue. Those precomputed shares indicate that a very small set of procedures drives most of the commercial flows reported here, so performance of those specific services largely determines the provider’s financial profile for each payer.
The provider’s payer mix is skewed toward Medicaid in scale: total Medicare revenue is $1.2M while total Medicaid revenue is $4.3M. In practical terms this means Medicaid-derived testing—especially U0004 and U0003—represents the majority of billed activity and revenue for the enterprise as reported in these datasets.
On Medicaid NATURAL STATE GENOMICS is a dominant in-state performer for COVID testing: U0004 shows 135.6K claims and $3.8M revenue and ranks #1 of 26 providers in-state (100th percentile; extreme outlier, far above typical state volume for this code), while U0003 shows 17.9K claims and $484.6K revenue and ranks #2 of 81 providers in-state (99th percentile; extreme outlier, far above typical state volume for this code). Those two codes together explain the large Medicaid revenue line and identify the provider as a major state-level source of high-throughput SARS‑CoV‑2 testing.
Medicare activity is concentrated in a few molecular codes where the provider posts relatively high national percentiles but the dataset labels them as typical volumes: 87798 ($720.9K, ranks #84 of 1319, 94th percentile; typical, unremarkable volume for this code), 87481 ($240.3K, ranks #63 of 1117, 94th percentile; typical, unremarkable volume for this code) and 87640 ($57K, ranks #76 of 1017, 93th percentile; typical, unremarkable volume for this code). One notable exception is 87109 (mycoplasma culture), where the provider ranks #1 of 37 nationally (100th percentile; extreme outlier, far above typical national volume for this code), indicating unusually high Medicare billing for that culture code compared with peers.
Operationally, the Medicaid line-item paid rates and claim counts underscore a high-throughput COVID testing capability: U0004 is reported with 135.6K claims at $28 avg paid/claim and U0003 with 17.9K claims at $27 avg paid/claim. By contrast many Medicare molecular codes report per-claim payments in the $34 range; these per-claim differentials and the massive Medicaid claim volumes point to scale-driven throughput economics oriented around SARS‑CoV‑2 high-volume testing.
The provider’s NPI was enumerated on 2020-01-09 (~6 years ago), a relatively recent start date that temporally aligns with the period of rapid expansion in molecular respiratory testing demand. That timeline, coupled with the Medicaid dominance for U0004/U0003, suggests program growth centered on pandemic-era high-throughput testing services rather than a long-established, broad-spectrum clinical laboratory practice.
Because nearly all revenue is concentrated in a handful of molecular/COVID codes (top-3 shares of 83.2% for Medicare and 99.1% for Medicaid), the business is highly dependent on continued demand and reimbursement stability for those specific services. From a payer analytics perspective this concentration creates exposure to changes in SARS‑CoV‑2 testing demand or coding/reimbursement policy, and it makes comparisons to a broader lab peer set especially sensitive to these few high-volume codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 21,200 | $30 | $720.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 7,070 | $30 | $240.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 1,680 | $30 | $57K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,640 | $30 | $55.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,640 | $30 | $55.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 210 | $140 | $29.1K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 560 | $30 | $19K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 240 | $70 | $17.5K |
| 87109 | The lab analyst performs a culture from any patient source and identifies any mycoplasma. | 1,090 | $20 | $16.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 230 | $30 | $5.8K |
Showing 1–10 of 12
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
38 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 135,610 | $30 | $3.8M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 17,950 | $30 | $484.6K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 270 | $30 | $6.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1,100 | $10 | $5.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1,040 | $10 | $5.2K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 80 | $60 | $4.7K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 1,040 | $1 | $4.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 990 | $1 | $4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 820 | $1 | $3.3K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 210 | $10 | $2.9K |
Showing 1–10 of 38
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
38 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 17 | 30 | 290 | $240 | $857.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 30 | 180 | $40 | $420.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9 | 30 | 160 | $70 | $259.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 14 | 20 | 340 | $40 | $197.3K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 15 | 20 | 420 | $40 | $192.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 71 | 100 | 900 | $40 | $168.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 46 | 70 | 830 | $40 | $146.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 50 | 70 | 830 | $40 | $144.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2 | 80 | 470 | $70 | $139.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 19 | 30 | 400 | $40 | $112.1K |
Showing 1–10 of 38
Other providers in the same ZIP code as Natural State Genomics LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Easter Seals Arkansas | AR | Developmentally Disabled Services Day Training Agency | $0 | $94.4M |
| Easter Seals Arkansas | AR | Physical Therapist | $0 | $2.2M |
| Bp Anesthesia, PLLC | AR | Certified Registered Nurse Anesthetist | $0 | $2M |
| Premier Gastroenterology Associates PLLC | AR | Ambulatory Surgical Clinic/Center | $1.3M | $242.8K |
| Endoscopy Center Of Little Rock,llc | AR | Ambulatory Surgical Clinic/Center | $420.1K | $2.2K |
| Battle Street Surgery Center, LLC | AR | Ambulatory Surgical Clinic/Center | $382.9K | $34.4K |
| Brent James | AR | Optometrist | $71.8K | $300.3K |
| Robert Svoboda | AR | Gastroenterology Physician | $352.9K | $0 |
| David Mcelreath | AR | Gastroenterology Physician | $310.3K | $0 |
| Donald Gauldin | AR | Ophthalmology Physician | $292.3K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.